BIO-TECHNE Corp vs Williams Companies Inc — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while Williams Companies Inc trades at $72.43 (market cap $87.41B). The key difference: Williams Companies Inc is far larger — about 7.7× BIO-TECHNE Corp's market cap, and Williams Companies Inc pays the higher dividend (2.94%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Williams Companies Inc for 58 Days on average.
| TECH | WMB | |
|---|---|---|
Market Cap | $11.37B | $87.41B |
Volume | 3,153,511 | 5,173,332 |
Sector | Health | Energy |
52-Week High | $72.61 | $79.40 |
52-Week Low | $43.31 | $56.51 |
Typical Hold Time | 63 Days | 58 Days |
Enterprise Value | $11.40B | $118.03B |
Dividend Yield | 0.44% | 2.94% |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Williams Companies (WMB) trades at $72.34, down 0.07% with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with 25.18% net income margin and 24.02% ROE, supported by stable cash flows from operations of $5.90B. Recent earnings show mixed results with Q1 2026 beating expectations while Q2 2026 slightly missed. The company benefits from growing natural gas demand driven by AI data center expansion and maintains a strategic position in midstream energy infrastructure.
WMB presents a compelling investment case with 79% analyst buy ratings and $87.27 consensus price target offering 21% upside. Key opportunities include dividend growth strategy and exposure to AI-powered energy demand, while risks involve energy market volatility and high debt levels of $24.74B long-term debt. The stock's valuation at 28.47 P/E appears justified by strong profitability and growth prospects in natural gas infrastructure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →